DIAMEDICA THERAPEUTICS INC COMMON SHARES (DMCAF) earnings
DMCAF earnings moved a median of +1.07% by the close. Quarterly and annual DMCAF reports and results, each read against the price at its own news timestamp. Back to the DMCAF overview →
30 measured DMCAF earnings events.
Where these DMCAF earnings landedvs 28 measured DMCAF earnings reactions
| Middle 50% of DMCAF earnings reactions | -3.25% to +2.30% |
|---|---|
| Median reaction (to close) | +1.07% |
| Measured reactions | 28 |
Point-in-time · zero look-ahead
Half of the 28 DMCAF earnings events with a measured close landed between -3.25% and +2.30%; 54% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 | Press release | +1.14% | +0.98% | |
| DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | Press release | -1.71% | +1.40% | |
| Form 10-Q DiaMedica Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -1.71% | +1.40% | |
| DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 | Press release | +3.69% | +1.51% | |
| Form 10-K DiaMedica Therapeutics For: Dec 31 | SEC filing · Form 10-K | -3.36% | -5.18% | |
| DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026 | Press release | +1.16% | +5.35% | |
| DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights | Press release | +0.95% | — | |
| Form 10-Q DiaMedica Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +0.95% | — | |
| DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025 | Press release | -1.21% | -4.21% | |
| DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | Press release | +2.86% | +22.45% | |
| Form 10-Q DiaMedica Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +2.86% | +22.45% | |
| DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025 | Press release | -0.64% | +0.00% | |
| DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights | Press release | +2.56% | +2.30% | |
| Form 10-Q DiaMedica Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +2.56% | +2.30% | |
| DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025 | Press release | — | -2.54% | |
| Form 10-K DiaMedica Therapeutics For: Dec 31 | SEC filing · Form 10-K | +0.00% | -13.17% | |
| DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025 | Press release | -0.18% | +3.70% | |
| DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results | Press release | -0.93% | -3.96% | |
| Form 10-Q DiaMedica Therapeutics For: Sep 30 | SEC filing · Form 10-Q | -0.93% | -3.96% | |
| DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 | Press release | -2.29% | -0.92% | |
| DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results | Press release | +2.13% | +2.13% | |
| Form 10-Q DiaMedica Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +2.13% | +2.13% | |
| DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024 | Press release | +0.00% | -0.29% | |
| DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results | Press release | -5.79% | -3.56% | |
| Form 10-Q DiaMedica Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -5.79% | -3.56% | |
| DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024 | Press release | +0.00% | +1.15% | |
| Form 10-K DiaMedica Therapeutics For: Dec 31 | SEC filing · Form 10-K | +0.00% | -3.15% | |
| DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results | Press release | +6.84% | +17.93% | |
| Form 10-Q DiaMedica Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +6.84% | +17.93% | |
| DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023 | Press release | -3.97% | +0.00% |
Keep exploring
More DMCAF: analyst actions → · SEC filings → · DMCAF overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SANTEN PHARM CO UNSP/ADR (SNPHY) | 2 | 0.00% | 0% |
| TODOS MED LTD ORD (TOMDF) | 2 | +8.33% | 50% |
| EUROFINS SCIENTIFIC SA (ERFSF) | 1 | +0.07% | 100% |
| IMRIS INC (IMRSQ) | 1 | 0.00% | 0% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.